Amgen’s subcutaneous TEPEZZA meets primary endpoint in Phase 3 TED trial
Amgen (NASDAQ:AMGN) has announced positive topline results from its Phase 3 clinical trial evaluating a subcutaneous formulation of TEPEZZA (teprotumumab-trbw) for adults with moderate-to-severe active Thyroid Eye Disease (TED).











